Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer
Study of Pd-1 Antibody in Combination with Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer
Sponsor: Army Medical University, China
Listed as NCT04516616, this PHASE2 trial focuses on Cervical Cancer and Uterine Cervical Cancer and remains ongoing. Sponsored by Army Medical University, China, it has been updated 9 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Apr 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Dec 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Apr 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
Feb 2021 — Apr 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Army Medical University, China
- Chongqing University Cancer Hospital
- First Affiliated Hospital of Chongqing Medical University
- Huazhong University of Science and Technology
- Obstetrics & Gynecology Hospital of Fudan University
- Peking University People's Hospital
- Qilu Hospital of Shandong University
- The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
- The Second Affiliated Hospital of Harbin Medical University
- Tianjin Medical University General Hospital
- Women's Hospital School Of Medicine Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .